Sanofi has dropped its respiratory syncytial virus (RSV) vaccine for toddlers after the candidate underperformed in a phase 3 study. The French Big Pharma was evaluating the intranasal live attenuated…
Welcome to this week’s Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren…
Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved treatments, prompting the San Diego biotech to plot a…
Sponsored By Seriant Oct 27, 2025 8:00am Clinical development is undergoing a structural shift. Protocols are growing more complex, budgets are shrinking, and expectations from regulators, payers, and patients continue…
Regeneron has given up on a CAR-T candidate acquired from 2seventy bio last year, before it entered the second part of a phase 1/2 lymphoma study. The dual-targeting CAR-T, dubbed…
Ventyx Biosciences’ cardiovascular disease drug cut levels of a biomarker for stroke and other serious risks by almost 80% within a week. The San Diego-based biotech has been evaluating the…
Roche has dropped five Chugai candidates from its clinical pipeline, echoing actions the Japanese business took earlier this year. Chugai revealed (PDF) the suspension of in-house development of the drug…
This week’s episode of “The Top Line” features a discussion about what’s working now in biotech and what isn’t. Recorded Oct. 7 at Fierce Biotech Week, this panel featuring leaders…
Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women from the virus in a large phase 3 trial, the biotech announced…
The cell therapy field has long held a transformative ambition: to create “off-the-shelf” treatments that can reach not just dozens, but thousands of patients. However, translating brilliant science into a…